Unlocking Innovation in Cannabinoids
In the cannabis industry, unlocking the potential of rare cannabinoids is crucial to advancing innovation and meeting the rising demand for precision health and wellness products.
Nature has gifted us with a remarkable plant—versatile, resilient, and valuable for its medicinal, recreational, and industrial uses. But when a plant can serve many purposes, scaling its production to meet demand is challenging, especially regarding rare cannabinoids.
While the cannabis plant produces over 100 cannabinoids, only a few—like THC and CBD—are typically discussed. Rare cannabinoids, such as THCV, CBC, and CBG, are found in trace amounts and often get overlooked. Yet, their potential therapeutic benefits are immense.
We don’t need to reinvent the wheel to harness these compounds efficiently. Similar to how modern pharmaceuticals have scaled naturally occurring compounds, BayMedica employs advanced manufacturing methods to produce rare cannabinoids at scale.
Accessing Rare Cannabinoids: Challenges and Solutions
The cannabis plant is home to over 600 active chemical compounds, including more than 100 cannabinoids. However, the industry’s focus has primarily been on THC and CBD, leaving many rare cannabinoids underutilized. These compounds are only present in the plant in trace amounts, making extracting them in significant quantities difficult.
For example, cultivating enough CBD for the epilepsy drug Epidiolex requires extensive resources, up to 23 football fields of greenhouse space to treat 40,000 patients. When we talk about rare cannabinoids like THCV or CBC, their production is even smaller—often less than 0.01% of the plant’s biomass.
Modern scientific techniques offer a solution to meet the growing demand for rare cannabinoids. Inspired by nature and driven by innovation, we at BayMedica use biosynthesis and other advanced methods to produce rare cannabinoids in commercial quantities.
Rare Cannabinoids Through Technology: Nature Meets Innovation
Many industries have found ways to scale nature’s best ingredients through modern manufacturing. The same approach applies to rare cannabinoids, bringing them from niche compounds to mass-market solutions.
Aspirin: From Willow Bark to Miracle Pill
Aspirin is a prime example of how nature’s compounds can be scaled up for mass use. People extracted the active compound, salicylic acid, for thousands of years from willow bark. However, modern science isolated and scaled this compound, transforming it into the widely accessible pain relief medication we know today. Similarly, we can produce rare cannabinoids at scale using modern technology.
Vitamin D in Milk: Health from the Lab
Have you ever wondered where the vitamin D in your milk comes from? It doesn’t naturally occur in milk or any abundant source we can harvest. Instead, scientific advances allow us to manufacture vitamin D at scale, supplementing milk to ensure we receive vital nutrients. Similarly, rare cannabinoids can be produced through biosynthesis and chemistry, making them accessible to more people.
Insulin: Saving Millions with Biosynthesis
Once extracted from animals, insulin is produced using biosynthesis, allowing mass production with greater safety and consistency. BayMedica uses the same technology as well as other modern techniques to manufacture rare cannabinoids, ensuring the same purity, consistency, and quality as the plant produces.
Hyaluronic Acid: Anti-Aging, Backed by Science
Hyaluronic acid is a naturally occurring compound in the body, valued for retaining moisture and promoting youthful skin. While it can be found in nature, most hyaluronic acid used in supplements and beauty products is produced in labs via biosynthesis—just like rare cannabinoids.
The Future of Rare Cannabinoids in the Cannabis Industry
Cannabis is an incredible plant, offering unparalleled medicinal, recreational, and industrial potential. However, while it excels in many areas, extracting rare cannabinoids directly from the plant is inefficient and costly.
At BayMedica, we’ve solved this problem by engineering advanced manufacturing platforms that produce rare cannabinoids like CBC, THCV, and CBDV in larger commercial quantities. These rare cannabinoids are bioidentical to those found in the plant and are produced at scale, making them accessible for various applications—from consumer packaged goods to pharmaceutical ingredients.
Our approach delivers high purity, consistent, scalable rare cannabinoids, empowering businesses to develop unique products while maintaining the quality and efficacy consumers demand.
Ready to Leverage Rare Cannabinoids for Your Business?
Rare cannabinoids offer a wealth of potential across various industries, from health and wellness to beauty and beyond. If you’re interested in integrating the power of rare cannabinoids into your products, reach out to our team at BayMedica to explore how we can help you unlock new possibilities.